Tatsuro Fukuhara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tatsuro Fukuhara has a total of 294 co-authors. Here are the top co-authors by number of shared publications:
- Eisaku Miyauchi
Department of Respiratory Medicine Tohoku University Hospital Sendai Japan
6 shared publications - Nobuhiro Tanuma
Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori, Japan
6 shared publications - Shunichi Sugawara
Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan
6 shared publications - Tomoyoshi Soga
Institute for Advanced Biosciences Keio University Tsuruoka Yamagata Japan
6 shared publications - Kayoko Hayashi
Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori, Japan
5 shared publications - Kyoji Tsurumi
Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori, Japan
5 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Table S1. Metabolomics data from AML cell lines treated with FK866
- 28 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Table S1. Metabolomics data from AML cell lines treated with FK866
- Open Access
- 28 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Table S1. Metabolomics data from AML cell lines treated with FK866
- 28 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Table S1. Metabolomics data from AML cell lines treated with FK866
- Open Access
- 28 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Figure S5. Effects of NAMPTi and NFD on hematopoiesis, related to Fig. 4.
- 28 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Figure S5. Effects of NAMPTi and NFD on hematopoiesis, related to Fig. 4.
- Open Access
- 28 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Table S1. Metabolomics data from AML cell lines treated with FK866
- 28 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Table S1. Metabolomics data from AML cell lines treated with FK866
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
Figure S1 from Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
Figure S1 from Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
- Open Access
- 13 October 2026
- Published by Elsevier in Clinical Lung Cancer
- Vol. 27 (10) , 37-50
Real-World Outcomes and Early Progressive Disease Analysis of Nivolumab and Ipilimumab Combination Therapy in Metastatic NSCLC: LIGHT-NING Study 2.5-Year Update
- 13 October 2026
- Published by Elsevier in Clinical Lung Cancer
- Vol. 27 (10) , 37-50
Open AccessReal-World Outcomes and Early Progressive Disease Analysis of Nivolumab and Ipilimumab Combination Therapy in Metastatic NSCLC: LIGHT-NING Study 2.5-Year Update
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (10) , 2529-2540
Nicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in NAD biosynthesis, is a potential therapeutic target in cancer. Acute myeloid leukemia (AML) is among cancer types exhibiting high NAMPT dependence, and elevated NAMPT activity is implicated in venetoclax resistance. Thus, pharmacologic NAMPT inhibitors (NAMPTi) have been developed as a promising therapeutic approach in some cancers. However, our current knowledge of in vivo factors that determine NAMPTi therapeutic efficacy is incomplete. In this study, using mouse models we found that NAMPTi efficacy against AML is limited by dietary nicotinic acid (NA). Specifically, NA and NA riboside (NAR), an NA-derived metabolite, promoted NAD biosynthesis independent of NAMPT and rescued AML cells from NAMPTi-mediated toxicity in vitro. Importantly, in AML xenograft models, dietary NA restriction, which selectively reduces circulating NAR levels, enhanced antitumor efficacy of NAMPTis and prolonged animal survival. Although the combination treatment caused transient hematologic toxicity, peripheral blood cell counts largely recovered after treatment. Our findings highlight systemic NAD precursor metabolism, including NAR, as a determinant of responses to NAMPT-targeted therapies. We conclude that NA restriction may improve the therapeutic efficacy of NAMPTis in AML. Significance: NAMPT is a potential therapeutic target in AML, but factors governing treatment response remain undefined. Building on findings that dietary NA maintains circulating NAR levels, we demonstrate that this pathway provides a critical escape mechanism from NAMPT inhibition. We show that NA restriction sensitizes AML to NAMPTis, significantly improving survival in vivo, identifying systemic NAD precursor metabolism as a key determinant of therapeutic efficacy.
- 1 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (10) , 2529-2540
Open AccessNicotinic Acid Restriction Potentiates NAMPT Inhibition in Acute Myeloid Leukemia Xenograft Models
Nicotinamide phosphoribosyltransferase (NAMPT), a key enzyme in NAD biosynthesis, is a potential therapeutic target in cancer. Acute myeloid leukemia (AML) is among cancer types exhibiting high NAMPT dependence, and elevated NAMPT activity is implicated in venetoclax resistance. Thus, pharmacologic NAMPT inhibitors (NAMPTi) have been developed as a promising therapeutic approach in some cancers. However, our current knowledge of in vivo factors that determine NAMPTi therapeutic efficacy is incomplete. In this study, using mouse models we found that NAMPTi efficacy against AML is limited by dietary nicotinic acid (NA). Specifically, NA and NA riboside (NAR), an NA-derived metabolite, promoted NAD biosynthesis independent of NAMPT and rescued AML cells from NAMPTi-mediated toxicity in vitro. Importantly, in AML xenograft models, dietary NA restriction, which selectively reduces circulating NAR levels, enhanced antitumor efficacy of NAMPTis and prolonged animal survival. Although the combination treatment caused transient hematologic toxicity, peripheral blood cell counts largely recovered after treatment. Our findings highlight systemic NAD precursor metabolism, including NAR, as a determinant of responses to NAMPT-targeted therapies. We conclude that NA restriction may improve the therapeutic efficacy of NAMPTis in AML. Significance: NAMPT is a potential therapeutic target in AML, but factors governing treatment response remain undefined. Building on findings that dietary NA maintains circulating NAR levels, we demonstrate that this pathway provides a critical escape mechanism from NAMPT inhibition. We show that NA restriction sensitizes AML to NAMPTis, significantly improving survival in vivo, identifying systemic NAD precursor metabolism as a key determinant of therapeutic efficacy.
- 27 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4571-4579
Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
Purpose: This study investigated the efficacy and safety of pembrolizumab and necitumumab as first-line therapy for patients with advanced non–small cell lung cancer (NSCLC) who had ≥50% programmed death-ligand 1 (PD-L1) expression. Patients and Methods: This nonrandomized, multicenter, open-label, single-arm phase II trial included patients with previously untreated advanced NSCLC who had a PD-L1 tumor proportion score of ≥50%. Patients received pembrolizumab and necitumumab every 3 weeks for up to 35 cycles. The primary endpoint was the investigator-assessed objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Results: The sample comprised 50 patients (38 men, 12 women; median age, 72 years; range, 51–90 years). The ORR was 76% (95% confidence interval, 61.9–86.9; P < 0.0001), with complete and partial response rates of 2% and 74%, respectively. Moreover, 10% and 8% of the patients had stable and progressive disease, respectively, whereas 6% could not be evaluated. The median PFS was 15.7 months, whereas the median OS was not reached at the time of analysis. The most common treatment-related adverse events were rash (64%) and hypomagnesemia (60%). Grade 3 interstitial lung disease occurred in five patients (10%), and grade 5 cardiac arrest occurred in one patient (2%). Conclusions: The pembrolizumab and necitumumab combination exhibited a promising ORR of 76% with a manageable safety profile in patients with NSCLC who had high PD-L1 expression. These findings highlight the need for further research on this regimen for patients with advanced NSCLC who have high PD-L1 expression.
- 27 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4571-4579
Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
Purpose: This study investigated the efficacy and safety of pembrolizumab and necitumumab as first-line therapy for patients with advanced non–small cell lung cancer (NSCLC) who had ≥50% programmed death-ligand 1 (PD-L1) expression. Patients and Methods: This nonrandomized, multicenter, open-label, single-arm phase II trial included patients with previously untreated advanced NSCLC who had a PD-L1 tumor proportion score of ≥50%. Patients received pembrolizumab and necitumumab every 3 weeks for up to 35 cycles. The primary endpoint was the investigator-assessed objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Results: The sample comprised 50 patients (38 men, 12 women; median age, 72 years; range, 51–90 years). The ORR was 76% (95% confidence interval, 61.9–86.9; P < 0.0001), with complete and partial response rates of 2% and 74%, respectively. Moreover, 10% and 8% of the patients had stable and progressive disease, respectively, whereas 6% could not be evaluated. The median PFS was 15.7 months, whereas the median OS was not reached at the time of analysis. The most common treatment-related adverse events were rash (64%) and hypomagnesemia (60%). Grade 3 interstitial lung disease occurred in five patients (10%), and grade 5 cardiac arrest occurred in one patient (2%). Conclusions: The pembrolizumab and necitumumab combination exhibited a promising ORR of 76% with a manageable safety profile in patients with NSCLC who had high PD-L1 expression. These findings highlight the need for further research on this regimen for patients with advanced NSCLC who have high PD-L1 expression.
- 21 August 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 229, 115693
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study
- 21 August 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 229, 115693
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study